After a median 22 years, clinically diagnosed retinopathy was 8.9% with lifestyle intervention versus 7.7% with control (OR 1.15; 95% CI 0.61 to 2.21); higher cumulative HbA1c was associated with higher risk.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
In 83 older men with obesity and low testosterone, adding testosterone to 6 months of lifestyle therapy did not improve HbA1c further (-0.5% vs -0.6%; P=0.35) and blunted the HDL and adiponectin rise.
Adding topiramate to metformin improved 6-month weight loss in women with PCOS, but the benefit was modest and paresthesia was more common.
In SURPASS-PEDS, weekly tirzepatide lowered HbA1c by 2.28 points versus placebo at 30 weeks and also reduced BMI in youth-onset type 2 diabetes.
ATTAIN-1 found that oral orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks in adults with obesity without diabetes.
In CHIRACIC, adrenalectomy improved home-blood-pressure normotension with less medication versus conservative management in unilateral mild autonomous cortisol secretion-associated hypertension.
In ACROINNOVA 1, monthly self-injected CAM2029 maintained IGF-1 control in 72.2% of adults with controlled acromegaly versus 37.5% on placebo withdrawal.
In STEP UP, semaglutide 7.2 mg reduced body weight by 18.7% versus 3.9% with placebo and outperformed semaglutide 2.4 mg in adults with obesity without diabetes.
In an open-label Graves disease RCT, methotrexate 10 mg weekly added to methimazole increased treatment withdrawal at 18 months, but remains investigational.
In gestational diabetes requiring medication, metformin-first oral therapy with glyburide rescue did not prove noninferior to insulin for preventing large-for-gestational-age birth.